Henrik Daub, Ph.D.

Prof. Daub is a pioneer and scientific leader in the field of proteomics-based drug discovery with more than 20 years of industry experience in the development and commercialization of state-of-the-art proteomics technologies. He is the scientific founder and CSO of NEOsphere Biotechnologies, a Munich-based company using data-independent high-throughput mass spectrometry (DIA-PASEF) for proteomic screening and mechanistic validation of degrader molecules. Previously, he was SVP Science & Technology at Evotec, where he led global efforts to discover targets for targeted protein degradation. Prior to that, he was a group leader at the Max Planck Institute of Biochemistry and scientific founder of the proteomics company Kinaxo Biotechnologies. Prof. Daub received his PhD in Biochemistry from the Max Planck Institute of Biochemistry and his venia legendi from the Technical University of Munich, where he is also a Professor of Biochemistry.